The results of a phase 2 trial of the triple agonist LY3437943 (Retatrutide) showed 24.2% weight loss at the highest dose (12 mg) in 48 weeks (23, 83)
Mental Health and Emotional Considerations Weight loss medications can affect mental and emotional wellbeing in various ways
Not for diagnostic, therapeutic, or consumer applications
More importantly for researchers considering stacking scenarios, the compound increased lean body mass without altering subcutaneous fat distribution
Over a thousand individuals, including medical professionals, celebrities, and the general public, have travelled from around the world to experience their weight-loss treatment
PlexusDx offers the Precision Peptide Genetic Test, which maps your individual variants across 14 metabolic pathways and 49 peptide targets, revealing 150+ personalized insights about your likelihood of success with specific GLP-1 therapies